Heron Therapeutics, Inc. (HRTX)

Price$1.05

Favorite Metrics

Price vs S&P 500 (26W)-26.12%

Price vs S&P 500 (4W)23.18%

Market Capitalization$187.09M

All Metrics

Book Value / Share (Quarterly)$0.08

P/TBV (Annual)15.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)12.88%

Cash Flow / Share (Quarterly)$-0.15

Price vs S&P 500 (YTD)-23.16%

Gross Margin (TTM)73.31%

Net Profit Margin (TTM)-13.04%

EPS (TTM)$-0.12

10-Day Avg Trading Volume1.74M

EPS Excl Extra (TTM)$-0.12

Revenue Growth (5Y)11.82%

EPS (Annual)$-0.12

ROI (Annual)-13.03%

Gross Margin (Annual)73.31%

Net Profit Margin (5Y Avg)-106.84%

Cash / Share (Quarterly)$0.25

Revenue Growth QoQ (YoY)-0.47%

ROA (Last FY)-7.89%

Revenue Growth TTM (YoY)7.36%

EBITD / Share (TTM)$-0.06

ROE (5Y Avg)-382.07%

Operating Margin (TTM)-8.96%

Cash Flow / Share (Annual)$-0.15

P/B Ratio13.05x

P/B Ratio (Quarterly)16.63x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)1.93x

Net Interest Coverage (TTM)-1.64x

ROA (TTM)-8.30%

EV / EBITDA (TTM)214.70x

EPS Incl Extra (Annual)$-0.12

Current Ratio (Annual)2.48x

Quick Ratio (Quarterly)1.42x

3-Month Avg Trading Volume1.79M

52-Week Price Return-42.93%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$-0.20

P/S Ratio (Annual)1.21x

Asset Turnover (Annual)0.61x

52-Week High$2.61

Operating Margin (5Y Avg)-103.72%

EPS Excl Extra (Annual)$-0.12

CapEx CAGR (5Y)-45.85%

Tangible BV CAGR (5Y)-36.47%

26-Week Price Return-19.23%

Quick Ratio (Annual)1.42x

13-Week Price Return-29.53%

Total Debt / Equity (Annual)9.81x

Current Ratio (Quarterly)2.48x

Enterprise Value$299.076

Revenue / Share Growth (5Y)-0.97%

Asset Turnover (TTM)0.64x

Book Value / Share Growth (5Y)-56.22%

Revenue / Employee (Annual)$1

Inventory Turnover (Annual)0.57x

Pretax Margin (Annual)-13.04%

Cash / Share (Annual)$0.25

3-Month Return Std Dev64.50%

Gross Margin (5Y Avg)58.20%

Net Income / Employee (TTM)$-0

ROE (Last FY)-140.90%

Net Interest Coverage (Annual)0.61x

EPS Basic Excl Extra (Annual)$-0.12

P/FCF (TTM)140.56x

Receivables Turnover (TTM)1.84x

Total Debt / Equity (Quarterly)9.81x

EPS Incl Extra (TTM)$-0.12

Receivables Turnover (Annual)1.84x

ROI (TTM)-13.21%

P/S Ratio (TTM)1.21x

Pretax Margin (5Y Avg)-106.84%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$0.11

Price vs S&P 500 (52W)-77.57%

Year-to-Date Return-19.23%

5-Day Price Return12.05%

EPS Normalized (Annual)$-0.12

ROA (5Y Avg)-41.62%

Net Profit Margin (Annual)-13.04%

Month-to-Date Return31.23%

Cash Flow / Share (TTM)$-0.93

EBITD / Share (Annual)$-0.06

Operating Margin (Annual)-8.96%

LT Debt / Equity (Annual)9.81x

ROI (5Y Avg)-73.08%

LT Debt / Equity (Quarterly)9.81x

EPS Basic Excl Extra (TTM)$-0.12

P/B Ratio (Annual)16.63x

Inventory Turnover (TTM)0.57x

Pretax Margin (TTM)-13.04%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-31.91%

Beta1.55x

P/FCF (Annual)20.81x

Revenue / Share (TTM)$0.82

ROE (TTM)-139.98%

52-Week Low$0.74

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.20

4.11

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HRTXHeron Therapeutics, Inc.	1.21x	7.36%	73.31%	—	$1.05
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Heron Therapeutics is a commercial-stage biopharmaceutical company with a portfolio of marketed products including APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. The company develops innovative treatments to address unmet patient needs.